News sentiment analysis powered by sentiment-insight.com
Sanofi looks to widen Dupixent use to treat 'smoker's...
Sanofi looks to widen Dupixent use to treat'smoker's lung' after second trial win. Use in COPD could add billions to the French drugmaker's growth prospects.
Mother of autistic children lodges complaint over emissions from Sanofi's Depakine drug plant -Le Monde Mother of two autistic children in France has lodged a legal complaint for endangering life. Melanie S. suspected she was exposed to airborne emissions from Sanofi's Depakine drug plant. Sanofi said it was not aware of the complaint and judicial authorities could not be immediately reached for comment.
CDC expedites release of more doses of infant RSV drug from Sanofi, AstraZeneca amid shortage Hospitals and pediatricians have been struggling to stock Beyfortus due to what Sanofi has described as "unprecedented demand" for the treatment. The shortage – and other issues related to insurance coverage – threatens to prevent infants from receiving critical protection against RSV.
Sanofi Taps Adviser for OTC Spinoff as Buyout Firms Circle Sanofi is working with an adviser to start preparations for a planned separation of its consumer health division. Burberry Group Plc warned this year’s revenue target may be out of reach after the UK trench-coat maker's sales barely grew.
Demand for RSV shot is so high, CDC is recommending it only for the most vulnerable The Beyfortus antibody shot, manufactured by drugmakers AstraZeneca and Sanofi, was approved by the Food and Drug Administration in July. Parts of the southern U.S. have been seeing a rise in RSV transmission in recent months, according to the CDC.
AstraZeneca prioritizes US for RSV drug amid surge in... AstraZeneca says it is prioritizing the U.S. market for additional doses of its respiratory syncytial virus (RSV) drug Beyfortus. The drug was approved in July to prevent the disease in infants and toddlers. The CDC has been asking for more of the antibody therapy that was co-developed with Sanofi.
UnitedHealth unit to add eight insulin products to its reimbursement list Eli Lilly, Novo Nordisk and Sanofi will have their insulin products added to the preferred status. The companies, which together control 90% of the U.S. insulin market, earlier this year pledged to lower the list prices.
UnitedHealth's unit to add eight insulin products to... UnitedHealth's unit to add eight insulin products to its reimbursement list. The move would limit out-of-pocket spend to $35 or less. Eli Lilly, Novo Nordisk and Sanofi will have their insulin products added to the preferred status.
Sanofi targeted in French price manipulation probe French prosecutors say they have launched an investigation into Sanofi over allegations the pharmaceutical giant spread false information. The preliminary investigation concerns financial communications about Dupixent - an anti-allergy medicine.
A new RSV shot for infants is in short supply The new, one-time shot is a lab-made antibody that helps the immune system fight off the virus. Sold under the brand name Beyfortus, the drug was developed by AstraZeneca and Sanofi. In July, the U.S. Food and Drug Administration approved it.
Reuters Health News Summary U.S. FDA approves Pfizer's vaccine for meningococcal disease. Sanofi seeing "unprecedented" demand for RSV therapy.
Sanofi seeing 'unprecedented' demand for RSV therapy French drugmaker Sanofi says it is seeing an "unprecedented level" of demand for its antibody therapy. The therapy, branded Beyfortus, was approved in July to prevent RSV in infants and toddlers.
Pro Take: Making medicines greener | Mint Novartis aims to achieve net-zero emissions across its value chain by 2040. Sanofi said it received a good response from the suppliers it reached.
Sanofi seeing 'unprecedented' demand for RSV therapy French drugmaker Sanofi said on Friday it was seeing an "unprecedented level" of demand for its antibody therapy to prevent respiratory syncytial virus. The therapy, branded Beyfortus, was approved in July to prevent RSV in infants and toddlers.
GoodRx to offer Sanofi's insulin injection for only $35 GoodRx has collaborated with Sanofi to offer the drugmaker's most-prescribed insulin injection Lantus for only $35. All Americans, regardless of insurance status, on prescriptions can buy a 30-day supply of the diabetes drug at a much lower price using a coupon.
Sanofi to Explore Acquisition of Cancer Drugmaker Mirati French pharmaceutical giant Sanofi is exploring a potential acquisition of cancer drugmaker Mirati Therapeutics. Mirati’s shares surged as much as 38% in New York trading. A sale would give Mirati further resources to help it commercialize the treatment.
Sanofi to explore acquisition of cancer drugmaker... Paris-based drugmaker Sanofi is exploring a potential acquisition of Mirati Therapeutics. Deliberations are ongoing and there is no certainty they will result in an agreement. Mirati's lung cancer drug, Krazati, was approved in December.
Sanofi to explore acquisition of cancer drugmaker Mirati- Bloomberg News Paris-based drugmaker Sanofi is exploring a potential acquisition of cancer drugmaker Mirati Therapeutics. Mirati's shares rose about 40% to $60.
Teva hopes Sanofi collaboration will lead to... Teva hopes Sanofi collaboration will lead to blockbuster IBD drug. Sanofi will invest $1.5 billion in the development of Teva's anti-TL1A drug. Phase 3 trials are not expected to begin until 2025. Teva has struggled to recover from the loss of exclusivity to Copaxone.
Updated COVID shots are coming. They're part of a trio of vaccines to block fall viruses | AP News The FDA recently approved Beyfortus, from Sanofi and AstraZeneca. The one-dose drug is recommended for all infants younger than 8 months.
Sign Up
